At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 3,182 enrolled
Drug / intervention
Lorcaserin 10 mg BID +1 moredrug
Likely dose
Lorcaserin 10 mg BIDfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management; A 104-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of Lorcaserin Hydrochloride in Obese Patients
In Brief
A Phase 3 clinical trial evaluating Lorcaserin 10 mg BID and Matching Placebo BID for Obesity. Completed, enrolled 3,182 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the weight loss effect of lorcaserin at the end of the first year of treatment (Week 52) and to assess the ability of lorcaserin to maintain weight loss at the end of the second year of treatment (Week 104)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2006
First PostedNov 2006
Primary CompletionFeb 2009
TodayJul 2026
First PostedNov 2, 2006
Enrollment StartNov 1, 2006
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 19.7 years ago
Interventions
Lorcaserin 10 mg BIDdrug
Lorcaserin 10 mg tablet each morning and evening for a duration of 52 or 104 weeks.
Matching Placebo BIDdrug
Matching placebo tablet each morning and evening for a duration of 52 or 104 weeks.